Natural Product Formulations for the Prevention and Treatment of Alzheimer’s disease: A Patent Review
Abstract
INTRODUCTION: Although considerable efforts have been made to develop effective therapeutic agents for Alzheimer's Disease (AD), neither a consensus concerning the pathogenesis of the disease nor a successful therapy for its treatment is yet available. The natural product chemistry brings tremendous diversity and abundant resource for medical needs. OBJECTIVES: The present review summarizes recent patents on natural extracts and derived drugs as agents for the prevention and treatment of AD. It also sums up the suggested mechanisms of action of the formulated natural remedies. CONCLUSION: It is now becoming well accepted that multiple factors contribute to the progression of AD. The pathogenesis of the disease involves amyloid-β cascade, tau hyperphosphorylation, oxidative stress, inflammation, mitochondrial dysfunction, protein misfolding, gene mutation, etc. It has been suggested that the multifactorial nature of AD pathogenesis requires the design of medicines with a wide spectrum of activity. Medicinal herbs are known to consist of multiple compounds and may implicate multiple mechanisms, thus being advantageous over the simple single-target drugs in the treatment of complex diseases. Indeed, natural products attract increased attention. In the last decades, they have become a major focus in the quest for AD remedies and may represent a real promise for curing the disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Alzheimer's disease onset and progression could be delayed or slowed down via the utilization of neuroprotective natural products that elicit their effects by affecting various pathological targets.
“As of now, it is reasonable to presume that AD onset and progression could be delayed or slowed down via the utilization of neuroprotective natural products that elicit their effects by affecting various pathological targets [47].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [47]
Cited by
Sorted by citations
BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
Moussa‐Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H. Y., & Al‐Tel, T. H. (2019) · Medicinal Research Reviews · doi:10.1002/med.21622 · Cited by 308 · see citing works
“Moreover, management of complicated diseases such as AD may require natural materials that contain various natural compounds with targeting multiple proteins rather than a single‐target synthetic compound.(75) Therefore, phytochemicals enjoy high 3D‐content and diverse molecular”
BackgroundA review: Pharmacology and pharmacokinetics of Schisandrin A
Fu, K., Zhou, H., Wang, C., Gong, L., Ma, C., Zhang, Y., & Li, Y. (2022) · Phytotherapy Research · doi:10.1002/ptr.7456 · Cited by 58 · see citing works
Sharma, K., Verma, R., Kumar, D., Nepovimová, E., Kuča, K., Kumar, A., Raghuvanshi, D., Dhalaria, R., & Puri, S. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115318 · Cited by 38 · see citing works
Šagud, M., Tudor, L., & Pivac, N. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1906223 · Cited by 31 · see citing works
“However, natural treatments have shown promising results in ‘in vitro’ and ‘in vivo’ studies and have been shown to improve the effect of existing AD treatments and thus represent strong candidates in ongoing and future clinical studies [132].”
BackgroundInfluentialComprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles
Chen, L., Mao, W., Ren, C., Li, J., & Zhang, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01802 · Cited by 36 · see citing works
The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment
Zieneldien, T., Kim, J., & Cao, C. (2022) · Geriatrics · doi:10.3390/geriatrics7020024 · Cited by 29 · see citing works
“As of now, it is reasonable to presume that AD onset and progression could be delayed or slowed down via the utilization of neuroprotective natural products that elicit their effects by affecting various pathological targets [47].”
BackgroundRen, Q., Gong, W.-G., Zhou, H., Shu, H., Wang, Y., & Zhang, Z. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-00698-w · Cited by 26 · see citing works
Gadiya, Y., Gribbon, P. M., Hofmann‐Apitius, M., & Zaliani, A. (2023) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2023.100069 · Cited by 24 · see citing works
Sharma, H. K., Borah, S., & Sarkar, P. (2020) · Pharmacognosy Research · doi:10.4103/pr.pr_84_19 · Cited by 19 · see citing works
“Scientific reports have suggested that AD progression can be prohibited by the interference of natural anti‐oxidants from a variety of plant sources from different geographical locations that hold out resistance against oxidative stress by scavenging the free radicals and by other mechanisms.[20,21] In recent epoch, i…”
BackgroundShi, J.-Y., Cai, W.-Q., Luo, X.-T., et al. (2023) · Biochemical Engineering Journal · doi:10.1016/j.bej.2023.108992 · Cited by 14 · see citing works
Manoharan, S. D., Hamid, H. A., Hashim, N. F. M., Cheema, M. S., Chiroma, S. M., Mustapha, M., & Mehat, M. Z. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148793 · Cited by 14 · see citing works
Rodrigues, B. R. I., Ventura, E., Moreira, P., Resende, R., Bicker, J., Santos, A. E., Pereira, C., Cruz, M. T., Robalo, M. P., da Silva, A. P., et al. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.12.005 · Cited by 8 · see citing works
“Between the years 1981 and 2019, 50 % of all new therapeutics approved by the FDA and similar worldwide organizations came from natural sources, and since the bioactivity of most plant species is mostly unknown, this still represents a huge unexploited resource (Koynova and Tenchov, 2018).”
Moreira, P., Matos, P., Figueirinha, A., Salgueiro, L., Batista, M. T., Branco, P. C., Cruz, M. T., & Pereira, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158812 · Cited by 10 · see citing works
“In accordance, over the past 20 years, about 50% of the over 1000 different compounds that have been studied as candidates for AD treatment are molecules obtained from natural sources, and some have already been tested in clinical trials [10,11].”
BackgroundMoreira, P., Macedo, J., Matos, P., Bicker, J., Fortuna, A. C., Figueirinha, A., Salgueiro, L., Batista, M. T., da Silva, A. P., Silva, S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117652 · Cited by 7 · see citing works
Shah, A. J., Mir, P. A., Adnan, M., Patel, M. B., Maqbool, M., Mir, R. H., & Masoodi, M. H. (2023) · ACS Omega · doi:10.1021/acsomega.3c05662 · Cited by 9 · see citing works
Kaur, S., Singh, B., Singh, H. B., Singh, B., Kumar, N., Rajput, A., Sidhu, D., Kaur, A., & Arora, S. (2021) · Current Drug Delivery · doi:10.2174/1567201818666211015152733 · Cited by 7 · see citing works
Nong, W., Chen, X., Chen, Y., Feng, X., Kong, W., Chi, R., Li, Y., & Wei, Z. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.04.006 · Cited by 9 · see citing works
“Compared with the SAMP8 accelerated aging mice treated with ibuprofen, ★ P < 0.05 and ★★ P < 0.01. multi-pathway pharmacological actions, toward becoming effective therapeutic (Koynova and Tenchov, 2018; Woon et al., 2022).”
InfluentialAegle marmelos (L.) Leaf Extract Improves Symptoms of Memory Loss Induced by Scopolamine in Rats
Thongsopha, C., Chaiwut, T., Thaweekhotr, P., Sudwan, P., Phasukdee, N., & Quiggins, R. (2024) · Foods · doi:10.3390/foods13040627 · Cited by 5 · see citing works
da Silva, A. W. R., & Biegelmeyer, R. (2020) · Revista Fitos · doi:10.32712/2446-4775.2020.909 · Cited by 3 · see citing works
NATURAL PRODUCT FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASEPreprint
Ahmad, S., Hafeez, A., Sharma, S. K., Ahmad, M., & Kumar, A. (2022) · doi:10.22541/au.166265946.63591247/v1 · Cited by 1 · see citing works
Alzheimer’s Disease Treatment Using Natural Foods: A Overview
Bhattacharya, T., Das, D., Chopra, H., & Baig, A. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-28780-0_51
Pathway to Register Natural Product-Derived Therapeutics
Maurya, A. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-9605-4_12
Asgharzadeh, N., Azizi, F., Hojjati, M. R., Roohi, L., Rabiei, Z., & Shahrani, M. (2024) · Future natural products. · doi:10.34172/fnp.2304-1246
Alzheimer's disease – An overview of nano herbal formulations
Patil, V. S., Patil, S., Patil, S. R., Pawar, A. S., & Shete, A. S. (2025) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2025.100042
- Authors
- Koynova, R., & Tenchov, B.
- Affiliations
- The Ohio State University (US)
- Medical University of Sofia (BG)
- Corresponding author
- Koynova, Rumiana
- Venue
- Recent Patents on Drug Delivery & Formulation
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2018-05-29
- Volume
- 12
- Issue
- 1
- Pages
- 23-39
- ISSN
- 1872-2113 (ISSN-L)
- OpenAlex
- W2774543119
- Cited by
- 25
- References
- 0
- Citations by year
- 2025: 3 · 2024: 6 · 2023: 5 · 2022: 5 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Recent Patents on Drug Delivery & Formulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, natural products, medicinal plants, natural extracts, drug formulation, amyloid-beta, tau hyperphosphorylation, oxidative stress, neuroinflammation, mitochondrial dysfunction, protein misfolding, mechanism of action
- MeSH terms
- Alzheimer Disease, Animals, Biological Products, Humans, Patents as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
